ABSTRACT
Introduction: In Mongolia, a total of 922000 patients have had COVID-19 infection in the last 2 years, and 2179 (0.24%) of them have died. Mongolia is considered as one of the countries that has successfully responded to COVID-19 pandemic due to its intensive vaccination, hospitalization of at-risk population and severe patients, and relatively low mortality rate. International studies reported that chronic kidney disease (CKD) increases risk of severe disease, adverse events and complications among COVID-19 patients. We aim to study COVID-19 clinical courses and prognosis in patients with CKD. Method(s): We have collected data from medical records of the First Central Hospital of Mongolia (FCHM) from April, 2021 to March, 2022 and data was assessed with the SPSS program. Result(s): We enrolled 125 patients in our study. Average age was 50.7+/-15.1 and 67(53.6%) of them were male, 58(46.4%) of them were female. 50(40%) patients were in CKD stage 1-4 (non-dialysis patients) and 75(60%) patients were in CKD stage 5 (dialysis patients). Among 125 patients, mild, moderate, severe, very-severe cases were 3(2.4%), 60(48%), 56(44.8%), and 6(4.8%) respectively. 15(12%) patients were treated in ICU, 9(7.2%) patients needed ventilator support, and 5(4%) patients died. Clinically, fever, cough, dyspnea, sore-throat, gastrointestinal symptoms, fatigue, and chest pain presented in 49(39.2%), 94(75.2%), 64(51.2%), 29(23.2%), 19(15.2%), 79(63.2%), and 32(25.6%) patients, respectively. 62(49.6% of total) patients were classified as severe and very-severe, 40(32%) of them were in CKD stage 5. 99(79.2%) patients of all patients were vaccinated against SARS-CoV-2 infection. 90(72%) have received remdesivir, 80(64%) patients have had steroid treatment. Conclusion(s): Dialysis patients had a tendency to have complications of COVID-19. We conclude that hospitalized patients with CKD at risk may have reduced the patient's risk of complications and affected prognosis. No conflict of interestCopyright © 2023